CalciMedica CEO Rachel Leheny has made a profit of US$75,000 from Investing.com

Rachel Leheny, Chief Executive Officer of CalciMedica, Inc. (NASDAQ:CALC), has earned 20,000 stammaktien from the Unternehmens with a price of 3.75 US dollars for Action. The amount of the transaction is approximately 75,000 US dollars. After this purchase, Leheny now directly receives 130,926 Aktien. You can make a number of individual investments by shifting a number of things before you can engage the partners and the Valence Investments SPV-Gesellschaften.

In other cases, CalciMedica has performed a biopharmaceutical drug, a powerful treatment in clinical trials and der Unternehmensführung. The company has established an active corporate mission with JonesTrading Institutional Services LLC as a manager. This report from CalciMedica is positive in the phase 2b CARPO study of the blessing, the additional treatment of pancreatitis with a systematic evaluation of the response system. The CalciMedica fund has issued a 2023 equity incentive plan for 1.5 million shares, after launching the campaign with the purchase of a loan.

The annual exchange of the internal economies of the Wahl of the Zwei Class-I director tower and the best quality of Moss Adams LLP as an affiliated Wirtschaftsprüfungsgesellschaft for the date of 31.12.2024 ended the Geschäftsjahr. Analyzers with Oppenheimer and single examination stop a positive assessment of the CalciMedica party and examine the development of the young clinical fortschritte and the market potential of the treatment of tertiary medicine.

InvestingPro Acknowledgment

Rachel Lehenys is a young entrepreneur at CalciMedica who comes to work with more knowledge of InvestingPro in a long time. The activities of the external parties require a beach yield of 72.09% for a year, while a young backwater of 8.07% is used per week. This volatility is reflected in an InvestingPro tip that is broader, saying that “the action going forward is a grimmer Einbruch hat.”

If the CEO’s investment gives a signal, CalciMedica will provide financial reimbursements. Ein InvestingPro-Tipp had then lost its “schnell Bargeld”, its negative EBITDA of -21.39 million US dollars for the last month until its best quarter 2024. This money loss is a critical factor for investors, which focuses on the market capitalization of US$37.52 million.

Moreover, CalciMedica has a strong liquidity position. An InvestingPro tip that prompted us to “make more money as debt abroad” was in the unrentable situation certain financial flexibility was possible.

For investors, who carry out some analysis, InvestingPro tips and acquaintances can generate them here. The platform list contains 8 other tips for CalciMedica in a way that provides one of the financial opportunities and market position of our companies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.